ライフサイエンスコーパス: intratumor

1 is study was to compare visual assessment of intratumor (18)F-FDG PET uptake distribution with a text

2 We hypothesize that intratumor adenosine impairs the ability of lymphokine-a

3 It involves an intratumor administration of a laser-absorbing dye and a

4 In contrast, intratumor administration of an Ad vector to individuals

5 ed murine mammary tumors (4T1) in vivo after intratumor administration.

6 in mice for toxicity and DNA delivery after intratumor and i.m. injection.

7 nocarcinoma (PDAC), and we hypothesized that intratumor bacteria might contribute to drug resistance

8 er infiltration and a striking change in the intratumor balance of Tregs and Teffs that directly corr

9 To model its in vivo role in the intratumor biomechanical environment, we investigated wh

10 ualization of capillaries, a high density of intratumor blood vessels was visualized in CPC mice.

11 A decreased influx of intratumor CD8(+) T cells was also observed.

12 the efficacy of anti-PD1 mAb and function of intratumor CD8(+) T cells.

13 analyses provide a framework to interrogate intratumor CD8(+) T-cell PD1 and immune PDL1 levels and

14 Intratumor cell heterogeneity can therefore be maintaine

15 Intratumor clones typically showed less diversity in met

16 mRNA profiles were highly similar in all 59 intratumor comparisons, in distinct contrast to the mark

17 tanercept-treated WT mice displayed enhanced intratumor content of high endothelial venules surrounde

18 ntiation of antitumor Th17 cells that induce intratumor CTL recruitment and subsequent regression of

19 We found that combined systemic IL-2 with an intratumor CXCR3 ligand (CXCL9) lead to significantly gr

20 the combined strategy of systemic IL-2 with intratumor CXCR3 ligand is more efficacious than either

21 mononuclear cells followed by enhancing the intratumor CXCR3 ligand levels to establish optimal CXCR

22 FACS analysis of the intratumor DCs showed that they were predominantly immat

23 5, we created an adenovirus-based vector for intratumor delivery, named Mobilan that drives expressio

24 studies have reported a correlation between intratumor dihydropyrimidine dehydrogenase (DPD) messeng

25 Cy5-RO5323441 was injected to study the intratumor distribution of RO5323441 with fluorescence m

26 iological features of tumors and control the intratumor distribution of these drug carriers should im

27 1P was cleared from the blood, reflecting an intratumor distribution process of SS1P that is independ

28 Intratumor distribution was assessed by fluorescence mic

29 mes in tumor vessels, suggesting a change in intratumor distribution; no significant effect of charge

30 KB cell xenografts (10-100 mg), whereas the intratumor distributions were investigated by autoradiog

31 The prevailing model for explaining intratumor diversity, the clonal evolution model, has re

32 what was predicted based on the increase in intratumor Doxil concentration.

33 emphasizing the need to directly measure the intratumor drug concentration.

34 d be a useful imaging tool for measuring the intratumor drug distribution.

35 8)F-FCP PET, we could image and identify the intratumor drug profile.

36 is behavior was traced to an aberrantly high intratumor FABP5/CRABP-II ratio.

37 therapy response, with resolution to reveal intratumor functional cancer heterogeneity.

38 model, gemcitabine resistance was induced by intratumor Gammaproteobacteria, dependent on bacterial C

39 been suggested as an ideal means of sampling intratumor genetic and epigenetic heterogeneity for diag

40 ting such complexity, increasing evidence of intratumor genetic heterogeneity (ITH) is emerging, both

41 African Americans had greater intratumor genetic heterogeneity and more basal gene exp

42 revealed that ductal carcinomas in situ show intratumor genetic heterogeneity at diagnosis and that t

43 Thirteen primary tumor foci exhibited intratumor genetic heterogeneity by FISH.

44 However, the extraordinary intratumor genetic heterogeneity in cancers revealed by

45 and triple-negative tumor prevalence but not intratumor genetic heterogeneity influenced the magnitud

46 Intratumor genetic heterogeneity is a key mechanism unde

47 This intratumor genetic heterogeneity poses a substantial cha

48 Intratumor genetic heterogeneity reflects the evolutiona

49 Intratumor genetic heterogeneity underlies the ability o

50 Intratumor genetic heterogeneity was greater in African

51 Intratumor genetic heterogeneity, which occurs in additi

52 asis through continuous prevention of severe intratumor hemorrhage and consequent cell death.

53 This suggests that the prevention of intratumor hemorrhage by platelets relies on the secreti

54 SL-DOX, MR imaging revealed the induction of intratumor hemorrhage in 63-75% of rats (n = 8).

55 rapid destabilization of tumor vessels with intratumor hemorrhage starting as soon as 30 min after i

56 platelet integrin activation did not lead to intratumor hemorrhage.

57 esting and degranulated platelets to prevent intratumor hemorrhage.

58 of putative drivers that underlie inter- and intratumor heterogeneities in CLL affecting disease prog

59 Intratumor heterogeneity (ITH) drives neoplastic progres

60 We explored the impact of neoantigen intratumor heterogeneity (ITH) on antitumor immunity.

61 and phenotypic features, a phenomenon termed intratumor heterogeneity (ITH).

62 r cell renal carcinomas (ccRCCs) can display intratumor heterogeneity (ITH).

63 Our results show varying degrees of intratumor heterogeneity among patients.

64 non-small-cell lung cancer (NSCLC), data on intratumor heterogeneity and cancer genome evolution hav

65 l approaches that are commonly used to infer intratumor heterogeneity and describe how these methodol

66 r relapse and a thorough characterization of intratumor heterogeneity and disease-resistant cell popu

67 ntext of tumor evolution and their impact on intratumor heterogeneity and drug development.

68 ew discusses the sources and consequences of intratumor heterogeneity and how these are recapitulated

69 ancer drug development is challenged by high intratumor heterogeneity and interpatient diversity.

70 ntributes to a mathematical understanding of intratumor heterogeneity and is also applicable to organ

71 The discovery of extensive intratumor heterogeneity and ongoing clonal adaptation i

72 mage features that allowed quantification of intratumor heterogeneity and peak standardized uptake va

73 events, and assess the relationship between intratumor heterogeneity and recurrence-free survival.

74 communicate at long range in vivo, inducing intratumor heterogeneity and resistance to treatment.

75 chromosomal instability were associated with intratumor heterogeneity and resulted in parallel evolut

76 light the importance of genetic diversity in intratumor heterogeneity and the value of analyzing tumo

77 However, the extent of intratumor heterogeneity as a result of tumor evolution

78 We have explored intratumor heterogeneity at the epigenetic level, due to

79 However, investigators are now elucidating intratumor heterogeneity at the single-cell level due to

80 urBayes, to estimate tumor purity and detect intratumor heterogeneity based on next-generation sequen

81 Intratumor heterogeneity can lead to underestimation of

82 Tumor complexity and intratumor heterogeneity contribute to subclonal diversi

83 ummarize important considerations related to intratumor heterogeneity during tumor evolution.

84 ion significantly affected quantification of intratumor heterogeneity for all textural parameters (P

85 We observed widespread intratumor heterogeneity for both somatic copy-number al

86 hybridization technique revealed inter- and intratumor heterogeneity for expression of the metastasi

87 mor were analyzed independently, we detected intratumor heterogeneity for PIK3CA mutations.

88 gnosis most tumors show a striking amount of intratumor heterogeneity in all measurable phenotypes; s

89 Intratumor heterogeneity in biologic properties and in r

90 However, some intratumor heterogeneity in chromosome content was found

91 There was pronounced intratumor heterogeneity in copy number alterations, tra

92 s, a fraction of genes exhibited significant intratumor heterogeneity in expression.

93 Our approach can generate reliable maps of intratumor heterogeneity in large numbers of patients wi

94 We wanted to prospectively investigate intratumor heterogeneity in relation to clinical outcome

95 Intratumor heterogeneity is a major clinical problem bec

96 understanding of the extent and evolution of intratumor heterogeneity is therefore of direct clinical

97 Accumulating evidence suggests that intratumor heterogeneity likely is the key to understand

98 Measurements of intratumor heterogeneity may also be used as biomarkers

99 Intratumor heterogeneity may foster tumor evolution and

100 Intratumor heterogeneity mediated through chromosome ins

101 Intratumor heterogeneity of 3p12.2, 6p21.2, and 8q11.23

102 Conversely, intratumor heterogeneity of chromosomal anomalies was id

103 umerous cancer types exhibit high inter- and intratumor heterogeneity of H1.0, with H1.0 levels corre

104 pment and may be informed by the presence of intratumor heterogeneity of KRAS and NRAS mutations.

105 solution and depth information to reveal the intratumor heterogeneity of mAb-IR700 distribution.

106 rovide a framework to decipher the impact of intratumor heterogeneity on key cancer phenotypes, and t

107 Intratumor heterogeneity remains a major obstacle to eff

108 Intratumor heterogeneity represents a major obstacle to

109 The extensive intratumor heterogeneity revealed by sequencing cancer g

110 que especially well suited to characterizing intratumor heterogeneity using counts of probes to genet

111 We characterized the consequences of intratumor heterogeneity using immunohistochemical analy

112 Accurate measurement of intratumor heterogeneity using parameters of texture on

113 tory gating and image noise on assessment of intratumor heterogeneity was evaluated using Cox regress

114 Intratumor heterogeneity was observed for a mutation wit

115 Substantial inter- and intratumor heterogeneity was observed for all investigat

116 Mutational intratumor heterogeneity was seen for multiple tumor-sup

117 Intratumor heterogeneity was visually scored (3-level sc

118 Our data also demonstrate extensive intratumor heterogeneity with respect to c-MYC copy numb

119 on, the adenoma and cancer further developed intratumor heterogeneity with the accumulation of nonran

120 ere, we investigate the additional impact of intratumor heterogeneity, a largely unstudied component

121 Intratumor heterogeneity, although present at the level

122 ility (CIN) contributes to cancer evolution, intratumor heterogeneity, and drug resistance.

123 of differentiating tumor types, visualizing intratumor heterogeneity, and segmenting anatomical stru

124 Intratumor heterogeneity, associated with heterogeneous

125 ally implementable pathologic definitions of intratumor heterogeneity, genetic diversity, and chromos

126 Different mechanisms contribute to intratumor heterogeneity, including genetic mutations, t

127 ppreciation for the extent and importance of intratumor heterogeneity, much attention in cancer resea

128 s, and the appearance of naturally occurring intratumor heterogeneity, thus recapitulating the stocha

129 To examine intratumor heterogeneity, we performed exome sequencing,

130 Intratumor heterogeneity, which fosters tumor evolution,

131 ploidy profiling analysis revealed extensive intratumor heterogeneity, with 26 of 30 tumor samples fr

132 ted genomic analysis that uncovers extensive intratumor heterogeneity, with most patients displaying

133 ppressors may provide a potent way to defeat intratumor heterogeneity.

134 nd DNA analysis, and revealed no significant intratumor heterogeneity.

135 emonstrated the ability to uncover molecular intratumor heterogeneity.

136 t is able to better resolve the biomolecular intratumor heterogeneity.

137 of different diseases with broad inter- and intratumor heterogeneity.

138 d to faster cell mixing and lower observable intratumor heterogeneity.

139 Surface markers that displayed intratumor heterogeneous expression among epithelial can

140 refilling of a delivery depot consisting of intratumor hydrogels completely abrogated tumor growth.

141 Relief of intratumor immunosuppression may increase considerably t

142 sis, increased tumor necrosis, and increased intratumor infiltration of CXCR3+ mononuclear cells, as

143 Moreover, treatment by direct intratumor injection into subcutaneous solid tumors of B

144 dy, we evaluated the effects of intermittent intratumor injection of a nonselective adenosine recepto

145 d potent systemic antitumor activities after intratumor injection of Ad-HT.

146 administration of IL-12 in combination with intratumor injection of anti-HLA-I antibody significantl

147 The data show that intratumor injection of CpG-oligodeoxynucleotides is a p

148 Intratumor injection of CpG-oligodeoxynucleotides was sh

149 Furthermore, intratumor injection of DNA-liposome complex containing

150 Intratumor injection of human CD24 and Her2/neu-specific

151 expression of costimulatory molecules or by intratumor injection of naive T cells.

152 Intratumor injection of the Ad5IL-12 vector to establish

153 tive expansion of the higher-avidity CTL and intratumor injection of the peptide may enhance the effe

154 CD8+ T-cell responses were induced by Ad-HT intratumor injection.

155 median age, 64 years) received a total of 83 intratumor injections with Adp53.

156 ere indistinguishable from those produced by intratumor inoculations of Burkitt's tumors with IP-10.

157 Reconstitution of intratumor IP-10 for a period of 8 wk resulted in a sign

158 IFN-gamma enzyme-linked immunospot assay and intratumor (IT) and circulating immune phenotypes (CD4 +

159 The elevated intratumor levels of adenosine might inhibit the antitum

160 therapeutic effects during PIT at different intratumor locations (e.g., tumor surface vs. deep tumor

161 stasizing cancer cells reach lymph nodes via intratumor lymphatic vessels is unknown.

162 The absence of intratumor lymphatics in hepatocellular carcinomas and l

163 The intratumor microenvironment generates phenotypically dis

164 abundance (P < 0.05) of edge-associated and intratumor microvessels, but not of stromally located mi

165 d a microdevice platform to recapitulate the intratumor oxygen gradients that drive the heterogeneous

166 In addition to spatial patterns of intratumor paracrine signaling, a possible cell-cycle-as

167 -PD1 therapy and remain dysfunctional unless intratumor PDL1(lo) immune cells are targeted.

168 ti-CD137 mAb treatment resulted in prolonged intratumor persistence of the OT1 CTL-effector cells and

169 on of COX-2 by celecoxib resulted in loss of intratumor PGE2 levels and reduced tumor growth in a dos

170 Intratumor phenotypic and functional heterogeneity have

171 f antimelanoma specific T cells suggest that intratumor-produced adenosine could impair the function

172 lls to infiltrate the tumor and increase the intratumor ratio of effector T cell/T reg cell.

173 n the tumor, highlight the importance of the intratumor ratio of effectors to regulators, and demonst

174 In contrast, intratumor regions had only zero to four gene changes at

175 ars to be adequate for the identification of intratumor regions of hypoxia.

176 e size of ROI(peak) caused more variation in intratumor response than did the location or shape of RO

177 colonic axis or in the relative quantity of intratumor stromal myofibroblasts as marked by the expre

178 esis patterns distinguishing region-specific intratumor subpopulations.

179 )F-FDG PET/CT have been reported to identify intratumor subvolumes at high risk of relapse after radi

180 above to 46% below the mean (CV, 17%) and an intratumor SUV(peak) response variation ranging from 49%

181 The variable ROI(peak) definition led to an intratumor SUV(peak) variation ranging from 49% above to

182 this limitation by using flow-sorted HRS and intratumor T cells and optimized low-input exome sequenc

183 lear factor kappaB pathway and a decrease in intratumor T-cell infiltration.

184 gefitinib on topotecan tECF penetration and intratumor topotecan distribution.

185 images were rigidly registered together, and intratumor tracer uptake distributions were compared.

186 Intratumor transgene mRNA was identified in 43% of asses

187 Intratumor Tregs are partly responsible for the developm

188 g penetration in tumors, associated with the intratumor upregulation of leukocyte-endothelial cell ad

189 glycolysis, and, more recently, the proposed intratumor uptake heterogeneity features.

190 The results of this study demonstrate that intratumor vaccination with a recombinant oncolytic aden

191 sults reveal the genome-wide architecture of intratumor variability in GB across multiple spatial sca

192 atterns of gene expression demonstrated that intratumor variation was substantially less than the tot

193 ice significantly reduced immunosuppression, intratumor vascularization, and local and metastatic bre

194 In B16 melanoma model, intratumor VBL injection induced apoptosis of melanoma c

195 noma was markedly reduced in C57BL/6 mice by intratumor VBL injection.

196 n in endothelial cells in edge-associated or intratumor vessels using this model might reveal mechani

197 The investigation of intratumor voxel doses indicates that mean tumor dose is

198 Intratumor voxels were classified into 4 clusters based

199 Intratumor voxels were stratified as being increased (PR